Prof P. Hudson

Peter Hudson

Chief Scientific Officer, Avipep Prt Ltd, VIC

Prof Peter Hudson, FTSE, BSc Hons (Adelaide, Australia), PhD (Cambridge, UK)

Peter is currently Director of the Victorian Cancer Biologics consortium for development of antibody therapies and is CSO of AviPep Pty Ltd. Peter is also Co-chair of HUPO-HAI (the Human Proteomics Antibody Initiative).  

Peter cloned the relaxin gene family and many other mammalian genes in the 80’s, wrote the first genetic engineering patents in Australia, and then focussed on antibody-based therapeutics since 1990. Peter has translated his basic discoveries in antibody design and tumour targeting into a current Phase 1clinical trial for prostate and ovarian cancer which will be completed in early 2014.

Peter was Deputy CEO and Scientific Director of the CRC for Diagnostics, a CSIRO Program and Theme Leader and Adjunct Professor (Department of Biochemistry, La Trobe University) and was elected to the ATSE Academy in 2002 and has over 100 publications and 25 patents.

VCB Head Office and AviPep Pty Ltd;
343 Royal Parade, Parkville, Vic, Australia 3052
Mobile +61.409806221;

Internet Information:
Avipep Pty Ltd (www.avipep.com)
HUPO-HAI (www.hupo.org/research/hai)
Relaxin (http://www.novartis.com/newsroom/media-releases/en/2013/1711047.shtml)